Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Kelonia Therapeutics Inc. have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics.
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.
Pompe disease is caused by a deficiency in the lysosomal enzyme acid α-glucosidase (GAA) that leads to accumulation of glycogen in the lysosomes, mainly seen in skeletal and cardiac muscles. Researchers from Duke University have developed a new murine model of Pompe disease, which recapitulates human infantile-onset disease. This model harbors the c.1826dupA mutation in the murine Gaa gene, which resembles the human GAA c.1826dupA (p.Y609*) mutation seen in infantile-onset Pompe disease.
Investigators from Tanta University and affiliated organizations have reported the discovery and preclinical characterization of novel carbonic anhydrase (CA) isoform II inhibitors as potential antiglaucoma agents.
Researchers from Zjengzhou University reported on the discovery and preclinical characterization of a novel PROTAC agent aimed at overcoming paclitaxel (Taxol) resistance in non-small-cell lung cancer treatment.
Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.
RSS
